Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating a fully integrated biosimilars platform spanning research, development, manufacturing and commercialization. - The deal positions Amneal to pursue more than $300 billion in projected global biologics loss-of-exclusivity opportunities over the next decade. - A biosimilar to Novartis' Xolair remains under FDA review, with a potential launch expected by the end of 2026 if approved, which would bring Amneal's U.S. biosimilar portfolio to six products. - Management has positioned biosimilars as a major long-term growth pillar within the company's Affordable Medicines business, which contributed $1.7 billion, or 57.8% of fiscal 2025 revenues.
- The generic drug industry is shifting from traditional small-molecule generics toward biosimilars, complex generics, and specialty injectables as price erosion pressures margins on commodity generics. - Sandoz reported Q1 2026 net sales of $2.76 billion with biosimilars growing 18% year-over-year, now accounting for nearly one-third of total revenues. - Teva, the world's largest generic drugmaker, expects its biosimilars business to generate $800 million in revenues by 2027, supported by its strategic partnership with Alvotech. - The Zacks Medical–Generic Drugs industry has surged approximately 44% over the past year, outperforming both the broader Zacks Medical sector and the S&P 500 Index.
- Alvotech's Reykjavik manufacturing facility successfully completed a routine FDA cGMP surveillance inspection on May 8, 2026, receiving a Form 483 with observations the company believes can be addressed quickly. - The biotechnology company remains well positioned to resubmit relevant Biologics License Applications in the second quarter of 2026, with FDA approval expected during 2026. - The inspection outcome demonstrates strong cGMP fundamentals and validates the robustness of improvements implemented since last year at the biosimilar manufacturing site. - Alvotech currently has five approved biosimilars marketed globally and nine disclosed biosimilar candidates in development targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
- Alvotech's AVT80, a biosimilar candidate to Entyvio (vedolizumab), met all primary endpoints in a pivotal pharmacokinetic study comparing safety, tolerability, and immunogenicity profiles in healthy adults. - The randomized, double-blind study evaluated a single 108 mg/0.68 mL subcutaneous injection and demonstrated pharmacokinetic similarity for both subcutaneous and intravenous administration routes. - The positive results enable Alvotech to proceed toward regulatory submissions for both AVT16 (intravenous) and AVT80 (subcutaneous) biosimilars targeting the $6.4 billion Entyvio market. - Entyvio is indicated for treating moderate to severe ulcerative colitis and Crohn's disease by targeting alpha-4-beta-7 protein on T helper lymphocytes that cause gastrointestinal inflammation.
- Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates across Canada, Australia, and New Zealand. - The partnership includes one ophthalmology biosimilar for Canada and three biosimilars across immunology and gastroenterology for Australia and New Zealand. - Sandoz will handle regulatory submissions and commercialization while Alvotech retains responsibility for development, clinical activities, and manufacturing. - The collaboration aims to expand patient access to critical biologic medicines sustainably and affordably following regulatory approvals.
- Alvotech founder Róbert Wessman will transition from CEO to Executive Chairman at the end of Q1 2026, continuing in a full-time capacity focused on strategy and business development. - Lisa Graver, former CEO of Alvogen and current Alvotech board member, has been appointed as the new Chief Executive Officer following a planned succession process. - The leadership transition comes as Alvotech operates with five biosimilars on the global market and maintains a pipeline of 30 products in development targeting autoimmune disorders, cancer, and other therapeutic areas. - Graver brings over 25 years of pharmaceutical leadership experience and has worked closely with Wessman for more than two decades across specialized generics and biosimilar sectors.
- Alvotech and Teva reached a settlement agreement with Regeneron allowing U.S. market entry for AVT06, a proposed biosimilar to Eylea (aflibercept), in the fourth quarter of 2026. - AVT06 has already received marketing approvals in Europe, Japan, and the UK, with clinical studies demonstrating high similarity to the reference product in treating neovascular AMD. - The settlement positions both companies for a potential U.S. launch pending FDA approval, following positive confirmatory clinical trial results announced in January 2024.
- Alvotech launched a $100 million senior unsecured convertible bond offering to support its $250 million R&D investment planned for 2026, maintaining its position as a leader in biosimilar development. - The company operates one of the most valuable biosimilar portfolios in the industry with 30 products under development and plans to launch 4 new products globally in 2026. - Despite FDA approval delays for key biosimilars including AVT05 (Simponi), AVT06 (Eylea), and potential delays for AVT03 (Prolia/Xgeva), Alvotech projects 2026 revenues of $650-700 million. - The company has secured a settlement with Regeneron for its Eylea biosimilar AVT06, granting U.S. market entry in Q4 2026, positioning Alvotech for significant growth despite regulatory challenges.
- The FDA approved Accord's Osvyrti/Jubereq (denosumab-desu) on November 20, 2025, marking the eighth biosimilar approval for Amgen's blockbuster osteoporosis drugs Prolia and Xgeva. - Amgen reached a confidential settlement with Hikma and Gedeon Richter on November 24, 2025, preventing commercial launch of their denosumab biosimilars until January 1, 2026. - Multiple denosumab biosimilar applications remain pending at FDA, including products from Teva, Amneal, and Alvotech/Dr. Reddy's, with ongoing patent litigation cases. - Amgen reported combined U.S. sales of $4.392 billion for Prolia ($2.885 billion) and Xgeva ($1.507 billion) in fiscal year 2024.
- The European Commission has approved Alvotech's AVT03 as a biosimilar to denosumab, providing access to an estimated $1.2 billion European market for osteoporosis and cancer-related bone complications. - The approval was based on extensive analytical and clinical data demonstrating equivalent pharmacokinetics, efficacy, safety, and immunogenicity to the original denosumab products Prolia and Xgeva. - Dr. Reddy's will lead commercialization in Europe under the Acvybra and Xbonzy brand names, marking a significant regulatory milestone for Alvotech's biosimilar platform. - Despite this European success, Alvotech faces ongoing challenges with FDA concerns regarding its AVT05 product and manufacturing facility inspections in the United States.
